Evidence map›Paper›PMID 42066065›Full record

ArticleACS chemical biology2026

A Novel Covalent Inhibitor Fragment for the SARS-CoV-2 Main Protease Identified by Target-Specific Deep Learning.

Weijun Zhou, Angel D Oliviera, Xuhang Dai, Jeffrey S Mugridge, Yingkai Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weijun ZhouDepartment of Chemistry, New York University, New York, New York 10003, United States.ORCID 0009-0001-8352-8200
Angel D OlivieraDepartment of Chemistry & Biochemistry, University of Delaware, Newark, Delaware 19716, United States.
Xuhang DaiDepartment of Chemistry, New York University, New York, New York 10003, United States.
Jeffrey S MugridgeDepartment of Chemistry & Biochemistry, University of Delaware, Newark, Delaware 19716, United States.ORCID 0000-0002-1553-3008
Yingkai ZhangDepartment of Chemistry, New York University, New York, New York 10003, United States.ORCID 0000-0002-4984-3354

Funding

This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2014 to 2024
$26.8M
Computational modulator design and machine learning to target protein-protein interactionsR35GM127040 · NIGMS · NEW YORK UNIVERSITY · PI Yingkai Zhang · 2018 to 2026
$4.6M
Selectivity and regulation of mRNA demethylation by iron-dependent dioxygenasesR35GM143000 · NIGMS · UNIVERSITY OF DELAWARE · PI MUGRIDGE, JEFFREY SCOTT · 2021 to 2025
$2.1M
Macromolecular X-ray Crystallographic Data Collection SystemS10OD026896 · OD · UNIVERSITY OF DELAWARE · PI BAHNSON, BRIAN J · 2020 to 2020
$580k
NIGMS NIH HHS P20 GM104316NIGMS NIH HHS R35 GM127040NIGMS NIH HHS R35 GM143000NIH HHS S10 OD026896
6 · The paper itself

Abstract

The SARS-CoV-2 main protease (M

Indexed as

Antiviral AgentsBetacoronavirusCoronavirus 3C ProteasesDeep LearningProtease InhibitorsSARS-CoV-2Drug DiscoveryHumansModels, Molecular3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors

Identifiers

PMID42066065
PMCPMC13184936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.